JP2024536106A5 - - Google Patents
Info
- Publication number
- JP2024536106A5 JP2024536106A5 JP2024518919A JP2024518919A JP2024536106A5 JP 2024536106 A5 JP2024536106 A5 JP 2024536106A5 JP 2024518919 A JP2024518919 A JP 2024518919A JP 2024518919 A JP2024518919 A JP 2024518919A JP 2024536106 A5 JP2024536106 A5 JP 2024536106A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163250918P | 2021-09-30 | 2021-09-30 | |
| US63/250,918 | 2021-09-30 | ||
| US202263374982P | 2022-09-08 | 2022-09-08 | |
| US63/374,982 | 2022-09-08 | ||
| PCT/US2022/077259 WO2023056355A2 (en) | 2021-09-30 | 2022-09-29 | Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536106A JP2024536106A (ja) | 2024-10-04 |
| JP2024536106A5 true JP2024536106A5 (https=) | 2025-09-24 |
Family
ID=85783647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518919A Pending JP2024536106A (ja) | 2021-09-30 | 2022-09-29 | 骨形成不全症の治療における抗スクレロスチン抗体の使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250011407A1 (https=) |
| EP (1) | EP4408884A4 (https=) |
| JP (1) | JP2024536106A (https=) |
| KR (1) | KR20240082380A (https=) |
| AU (1) | AU2022357544A1 (https=) |
| CA (1) | CA3233220A1 (https=) |
| MX (1) | MX2024003828A (https=) |
| TW (1) | TW202323278A (https=) |
| WO (1) | WO2023056355A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025212547A1 (en) * | 2024-04-05 | 2025-10-09 | Amgen Inc. | Methods of treating osteogenesis imperfecta |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011517672A (ja) * | 2008-03-24 | 2011-06-16 | アボツト・バイオテクノロジー・リミテツド | 骨損失を治療するための方法及び組成物 |
| MA41142A (fr) * | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| KR20190037261A (ko) * | 2016-08-08 | 2019-04-05 | 암젠 인크 | 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법 |
| MX2019007161A (es) * | 2016-12-21 | 2020-02-12 | Mereo Biopharma 3 Ltd | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. |
| US10961305B2 (en) * | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| GB201810746D0 (en) * | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
-
2022
- 2022-09-29 AU AU2022357544A patent/AU2022357544A1/en active Pending
- 2022-09-29 EP EP22877568.0A patent/EP4408884A4/en active Pending
- 2022-09-29 JP JP2024518919A patent/JP2024536106A/ja active Pending
- 2022-09-29 KR KR1020247013976A patent/KR20240082380A/ko active Pending
- 2022-09-29 US US18/696,578 patent/US20250011407A1/en active Pending
- 2022-09-29 WO PCT/US2022/077259 patent/WO2023056355A2/en not_active Ceased
- 2022-09-29 MX MX2024003828A patent/MX2024003828A/es unknown
- 2022-09-29 CA CA3233220A patent/CA3233220A1/en active Pending
- 2022-09-30 TW TW111137296A patent/TW202323278A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240417455A1 (en) | Treatment for rheumatoid arthritis | |
| JP2025172841A5 (https=) | ||
| JP2018184417A5 (https=) | ||
| JP2022160685A5 (https=) | ||
| JP2014524748A5 (https=) | ||
| RU2015107889A (ru) | Композиция, содержащая два антитела, сконструированных так, чтобы они обладали пониженной и повышенной эффекторной функцией | |
| JP2019517549A5 (https=) | ||
| JP2018108086A5 (https=) | ||
| RU2015112576A (ru) | Комбинированная терапия с использованием антитела против cd20 типа ii и селективного ингибитора bcl-2 | |
| JP2017507954A5 (https=) | ||
| JP2022532927A5 (https=) | ||
| JP2017534646A5 (https=) | ||
| JP2024531151A5 (https=) | ||
| JP2019162119A5 (https=) | ||
| JP2024516698A5 (https=) | ||
| JP2021530438A5 (https=) | ||
| JP2018535961A5 (https=) | ||
| JP2019521156A5 (https=) | ||
| JP2022523530A5 (https=) | ||
| JP2015172060A5 (https=) | ||
| JP2023545084A5 (https=) | ||
| JP2024540226A5 (https=) | ||
| JP2023500337A5 (https=) | ||
| JP2024536106A5 (https=) | ||
| JP2021523881A5 (https=) |